{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:31:13Z","timestamp":1780471873356,"version":"3.54.1"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jpeds.2021.01.068","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T17:04:28Z","timestamp":1612371868000},"page":"245-256.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Morbidity and Disability in Juvenile Localized Scleroderma: The Case for Early Recognition and Systemic Immunosuppressive Treatment"],"prefix":"10.1016","volume":"234","author":[{"given":"Suzanne C.","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"O'Neil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2021.01.068_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/acr2.1019","article-title":"Baseline description of the juvenile localized scleroderma subgroup from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry","volume":"1","author":"Wu","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/bjd.17312","article-title":"Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma","volume":"180","author":"Kurzinski","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib3","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.3899\/jrheum.171381","article-title":"New Features for measuring disease activity in pediatric localized scleroderma","volume":"45","author":"Li","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib4","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3899\/jrheum.190311","article-title":"Initial Results from a pilot comparative effectiveness study of 3 methotrexate-based consensus treatment plans for juvenile localized scleroderma","volume":"47","author":"Li","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1001\/archderm.1958.01560120069011","article-title":"The prognosis of localized scleroderma","volume":"78","author":"Curtis","year":"1958","journal-title":"AMA Arch Derm"},{"key":"10.1016\/j.jpeds.2021.01.068_bib6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01241398-200007000-00005","article-title":"Scleroderma in childhood: a 35-year history of cases and review of the literature","volume":"20","author":"Bottoni","year":"2000","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.jpeds.2021.01.068_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.pcl.2018.04.002","article-title":"Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis","volume":"65","author":"Li","year":"2018","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.jpeds.2021.01.068_bib8","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1002\/art.21264","article-title":"Localized scleroderma in childhood is not just a skin disease","volume":"52","author":"Zulian","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/1534734607308731","article-title":"Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma","volume":"6","author":"Wollina","year":"2007","journal-title":"Int J Low Extrem Wounds"},{"key":"10.1016\/j.jpeds.2021.01.068_bib10","first-page":"73","article-title":"The epidemiology of morphea (localized scleroderma) in Olmstead County 1960-1993","volume":"24","author":"Peterson","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/acr.20070","article-title":"Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland","volume":"62","author":"Herrick","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jpeds.2021.01.068_bib12","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nrrheum.2010.121","article-title":"Prevalence and burden of pediatric-onset systemic lupus erythematosus","volume":"6","author":"Kamphuis","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib13","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3389\/fimmu.2019.00908","article-title":"Immunopathogenesis of pediatric localized scleroderma","volume":"10","author":"Torok","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib14","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1111\/jdv.14197","article-title":"Localized scleroderma: clinical and epidemiological features with emphasis on adulthood- versus childhood-onset disease differences","volume":"31","author":"Lis-Swiety","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib15","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1097\/01.bor.0000245727.40630.c3","article-title":"Localized scleroderma","volume":"18","author":"Laxer","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib16","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1212\/01.wnl.0000334474.88923.e3","article-title":"Neurologic manifestations of localized scleroderma. A case report and literature review","volume":"71","author":"Kister","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jpeds.2021.01.068_bib17","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.autrev.2018.02.004","article-title":"Disease course and long-term outcome of juvenile localized scleroderma: experience from a single pediatric rheumatology centre and literature review","volume":"17","author":"Martini","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jpeds.2021.01.068_bib18","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780390624","article-title":"Childhood-onset scleroderma","volume":"39","author":"Vancheeswaran","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib19","first-page":"171","article-title":"Localized scleroderma in adults and children. Clinical and laboratory investigations on 239 cases","volume":"13","author":"Marzano","year":"2003","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/pde.13336","article-title":"Orthopedic complications of linear morphea: implications for early interdisciplinary care","volume":"35","author":"Schoch","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib21","first-page":"4535804","article-title":"Extensive bone lengthening for a patient with linear morphea","volume":"2018","author":"Mishima","year":"2018","journal-title":"Case Rep Orthop"},{"key":"10.1016\/j.jpeds.2021.01.068_bib22","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1440-1754.2012.02435.x","article-title":"Odontostomatologic involvement in juvenile localised scleroderma of the face","volume":"48","author":"Trainito","year":"2012","journal-title":"J Paediatrics Child Health"},{"key":"10.1016\/j.jpeds.2021.01.068_bib23","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.survophthal.2016.03.009","article-title":"Ophthalmological manifestations of Parry-Romberg syndrome","volume":"61","author":"Bucher","year":"2016","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semarthrit.2013.05.002","article-title":"Neurologic involvement in scleroderma: a systematic review","volume":"43","author":"Amaral","year":"2013","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib25","article-title":"Localised scleroderma en coup de sabre affecting the skin, dentition and bone tissue within craniofacial neural crest fields. Clinical and radiographic study of six patients","volume":"20","author":"Lauresen","year":"2019","journal-title":"Eur Archives Paed Dentistry"},{"key":"10.1016\/j.jpeds.2021.01.068_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00006534-199005000-00001","article-title":"Clinical and ultrastructural studies of Romberg's hemifacial atrophy","volume":"85","author":"Pensler","year":"1990","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jpeds.2021.01.068_bib27","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1136\/bjo.2007.116038","article-title":"Ocular involvement in children with localised scleroderma: a multi-centre study","volume":"91","author":"Zannin","year":"2007","journal-title":"Br J Opthalmol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib28","doi-asserted-by":"crossref","first-page":"e1715","DOI":"10.1542\/peds.2014-0019","article-title":"Headaches as a presenting symptom of linear morphea en coup de sabre","volume":"134","author":"Polcari","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2021.01.068_bib29","doi-asserted-by":"crossref","first-page":"3496","DOI":"10.1002\/art.38853","article-title":"Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort","volume":"66","author":"Condie","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib30","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/bjd.13514","article-title":"Disease recurrence in localized scleroderma: a retrospective analysis of 344 patients with paediatric- or adult-onset disease","volume":"172","author":"Mertens","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib31","first-page":"343","article-title":"Scleroderma in childhood","volume":"20","author":"Kornreich","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib32","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/ard.35.3.189","article-title":"Scleroderma in childhood","volume":"35","author":"Ansell","year":"1976","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2021.01.068_bib33","doi-asserted-by":"crossref","first-page":"849","DOI":"10.7326\/0003-4819-104-6-849","article-title":"Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities","volume":"104","author":"Falanga","year":"1986","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jpeds.2021.01.068_bib34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1136\/adc.49.11.861","article-title":"Scleroderma in childhood. Report of 5 cases","volume":"49","author":"Goel","year":"1974","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jpeds.2021.01.068_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/archderm.1948.01520200004001","article-title":"Linear scleroderma; association with abnomalities of the spine and nervous system","volume":"58","author":"Rubin","year":"1948","journal-title":"Arch Derm Syphilol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib36","first-page":"741","article-title":"Arthritis, myositis, and growth defects of bone in children with localized scleroderma","volume":"23","author":"Sandborg","year":"1980","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib37","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/0049-0172(94)90028-0","article-title":"Localized scleroderma in childhood: a report of 30 cases","volume":"23","author":"Uziel","year":"1994","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib38","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1097\/01241398-199311000-00020","article-title":"Focal scleroderma in children: an orthopaedic perspective","volume":"13","author":"Buckley","year":"1993","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.jpeds.2021.01.068_bib39","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0022-3476(62)80064-X","article-title":"Focal scleroderma. Report of 19 cases in children","volume":"60","author":"Chazen","year":"1962","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2021.01.068_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12969-018-0295-0","article-title":"Multi-centre national audit of juvenile localised scleroderma: describing current UK practice in disease assessment and management","volume":"16","author":"Lythgoe","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jpeds.2021.01.068_bib41","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/art.1780350502","article-title":"The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis","volume":"35","author":"Hochberg","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib42","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.jaad.2010.09.006","article-title":"A systematic review of morphea treatments and therapeutic algorithm","volume":"65","author":"Zwischenberger","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/ddg.12724","article-title":"German guidelines for the diagnosis and therapy of localized scleroderma","volume":"14","author":"Kreuter","year":"2016","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jpeds.2021.01.068_bib44","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/jdv.14458","article-title":"European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes","volume":"31","author":"Knobler","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib45","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/rheumatology\/35.4.364","article-title":"Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, fol- lowed by a 24 week observational trial","volume":"35","author":"van den Hoogen","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib46","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0190-9622(98)70079-9","article-title":"Low-dose methotrexate in the treatment of widespread morphea","volume":"39","author":"Seyger","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib47","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/acr.21687","article-title":"Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma","volume":"64","author":"Li","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2021.01.068_bib48","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/art.30264","article-title":"Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial","volume":"63","author":"Zulian","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib49","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3899\/jrheum.090708","article-title":"Treatment of pediatric localized scleroderma: results of a survey of North American pediatric rheumatologists","volume":"37","author":"Li","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib50","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1136\/annrheumdis-2018-214697","article-title":"Consensus-based recommendations for the management of juvenile localised scleroderma","volume":"78","author":"Zulian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jpeds.2021.01.068_bib51","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1001\/archderm.1994.01690050133027","article-title":"Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients","volume":"130","author":"Joly","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib52","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1007\/s10067-019-04600-7","article-title":"Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy","volume":"38","author":"Ten Klooster","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib53","first-page":"382","article-title":"Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study","volume":"36","author":"Toledano","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib54","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib55","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2340\/00015555-2411","article-title":"Drug survival and predictors of drug survival for methotrexate treatment in a retrospective cohort of adult patients with localized scleroderma","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib56","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jaad.2014.11.019","article-title":"Attitudes and trends in the treatment of morphea: a national survey","volume":"72","author":"Strickland","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib57","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.jaad.2012.01.011","article-title":"Morphea in adults and children cohort II: Patients with morphea experience delay in diagnosis and large variation in treatment","volume":"67","author":"Johnson","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib58","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/pde.13281","article-title":"Discordance of pediatric morphea treatment by pediatric dermatologists","volume":"35","author":"Tollefson","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12969-018-0255-8","article-title":"Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting","volume":"16","author":"Ferrara","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"key":"10.1016\/j.jpeds.2021.01.068_bib60","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/pde.14074","article-title":"A retrospective study: Impact of consensus treatment plans on systemic therapy of pediatric morphea","volume":"37","author":"Do","year":"2020","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib61","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s00234-014-1448-6","article-title":"CNS imaging findings associated with Parry-Romberg syndrome and en coup de sabre: correlation to dermatologic and neurologic abnormalities","volume":"57","author":"Doolittle","year":"2015","journal-title":"Neuroradiology"},{"key":"10.1016\/j.jpeds.2021.01.068_bib62","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s00247-018-4177-x","article-title":"The central nervous system manifestations of localized craniofacial scleroderma: a study of 10 cases and literature review","volume":"48","author":"Maloney","year":"2018","journal-title":"Pediatr Radiol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib63","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clineuro.2014.10.005","article-title":"Recurrent myelitis in localized scleroderma","volume":"127","author":"Miyamoto","year":"2014","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.jpeds.2021.01.068_bib64","doi-asserted-by":"crossref","first-page":"101457","DOI":"10.1016\/j.msard.2019.101457","article-title":"Extensive linear scleroderma en coup de sabre with exertion-induced hemiplegic migraine","volume":"37","author":"Martins","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jpeds.2021.01.068_bib65","doi-asserted-by":"crossref","first-page":"e363","DOI":"10.1111\/pde.13647","article-title":"Remission of seizures with immunosuppressive therapy in Parry-Romberg syndrome and en coup de sabre linear scleroderma: case report and brief review of the literature","volume":"35","author":"Anderson","year":"2018","journal-title":"Pediatr Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s13023-019-1015-7","article-title":"Linear scleroderma \u201cen coup de sabre\u201d with extensive brain involvement\u2014Clinicopathologic correlations and response to anti-Interleukin-6 therapy","volume":"14","author":"Magro","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jpeds.2021.01.068_bib67","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1365-2133.2011.10600.x","article-title":"Misdiagnosis and delay in referral of children with localized scleroderma","volume":"165","author":"Weibel","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib68","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jaad.2006.10.959","article-title":"En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients","volume":"56","author":"Tollefson","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib69","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.3899\/jrheum.081284","article-title":"The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures","volume":"36","author":"Arkachaisri","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib70","first-page":"72","article-title":"Reliability and validity of a new skin activity measure for localized scleroderma [abstract]","author":"Li","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib71","first-page":"72","article-title":"Capturing the range of disease involvement in localized scleroderma: the total morbidity score [abstract]","author":"Li","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib72","doi-asserted-by":"crossref","first-page":"W376","DOI":"10.2214\/AJR.12.9335","article-title":"Response evaluation of musculoskeletal involvement in patients with deep morphea treated with methotrexate and prednisolone: a combined MRI and clinical approach","volume":"200","author":"Schanz","year":"2013","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib73","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/acr.20407","article-title":"Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma","volume":"63","author":"Li","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jpeds.2021.01.068_bib74","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/jdv.16308","article-title":"Prospective evaluation of treatment response and disease reversibility of paediatric localized scleroderma (morphoea) to steroids and methotrexate using multi-modal imaging","volume":"34","author":"Weibel","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib75","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jaad.2012.03.036","article-title":"A long-term follow-up study of methotrexate in juvenile localized scleroderma (morphea)","volume":"67","author":"Zulian","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib76","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2133.2011.10535.x","article-title":"Relapse after systemic treatment in paediatric morphoea","volume":"166","author":"Mirsky","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib77","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1365-2133.2006.07497.x","article-title":"Evaluation of methotrexate and corticosteroids for the treatment of localized scleroderma (morphoea) in children","volume":"155","author":"Weibel","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib78","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/rheumatology\/kep244","article-title":"Successful treatment of severe or methotrexate-resistant juvenile localized scleroderma with mycophenolate mofetil","volume":"48","author":"Martini","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.jpeds.2021.01.068_bib79","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2340\/00015555-2297","article-title":"Use of mycophenolate mofetil in patients with severe localized scleroderma resistant or intolerant to methotrexate","volume":"96","author":"Mertens","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib80","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5301\/jsrd.5000259","article-title":"Tocilizumab is a promising treatment option for therapy resistant juvenile localized scleroderma patients","volume":"2","author":"Foeldvari","year":"2018","journal-title":"J Scleroderma Relat Disorders"},{"issue":"Suppl 106","key":"10.1016\/j.jpeds.2021.01.068_bib81","first-page":"211","article-title":"Tocilizumab in two children with pansclerotic morphoea: a hopeful therapy for refractory cases?","volume":"35","author":"Martini","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jpeds.2021.01.068_bib82","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1093\/rheumatology\/kex382","article-title":"Tocilizumab as a potential therapeutic option for children with severe, refractory juvenile localized scleroderma","volume":"57","author":"Lythgoe","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.jpeds.2021.01.068_bib83","first-page":"keaa873","article-title":"Preliminary evidence on abatacept safety and efficacy in refractory juvenile localized scleroderma","author":"Li","year":"2020","journal-title":"Rheumatology"},{"key":"10.1016\/j.jpeds.2021.01.068_bib84","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.semarthrit.2020.03.020","article-title":"Abatacept in the treatment of localized scleroderma: apediatric case series and systematic literature review","volume":"50","author":"Kalampokis","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jpeds.2021.01.068_bib85","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.semarthrit.2015.06.006","article-title":"Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles","volume":"45","author":"Torok","year":"2015","journal-title":"Semin Arthritis Rheum"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347621001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347621001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:07:45Z","timestamp":1758359265000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347621001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":85,"alternative-id":["S0022347621001025"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2021.01.068","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Morbidity and Disability in Juvenile Localized Scleroderma: The Case for Early Recognition and Systemic Immunosuppressive Treatment","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2021.01.068","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}